NASDAQ:SELB Selecta Biosciences Stock Forecast, Price & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Selecta Biosciences Inc Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $2.42 +0.06 (+2.54 %) (As of 09/25/2020 12:00 AM ET) Add Compare Share Today's Range$2.36Now: $2.42▼$2.4550-Day Range$2.18MA: $2.50▼$2.7152-Week Range$1.28Now: $2.42▼$4.83Volume445,485 shsAverage Volume1.36 million shsMarket Capitalization$259.29 millionP/E RatioN/ADividend YieldN/ABeta1.3 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial Media Selecta Biosciences, Inc., a clinical-stage biopharmaceutical company, researches and develops nanoparticle immunomodulatory drugs for the treatment and prevention of human diseases. Its proprietary pipeline includes therapeutic enzymes, gene therapies, and other products and product candidates affected by undesired immune responses. The company's lead product is SEL-212 that in Phase II clinical trials for the treatment of chronic refractory gout. It is also developing SEL-403, which is in Phase I clinical trials for the treatment of patients with malignant pleural or peritoneal mesothelioma. In addition, the company engages in the development of gene therapy product candidates that are in preclinical development for rare inborn errors of metabolism, including SEL-302, a therapy program for the treatment methylmalonic academia; and SEL-313, a product candidate to treat ornithine transcarbamylase deficiency. Selecta Biosciences, Inc. has license and collaboration agreements with Spark Therapeutics, Massachusetts Institute of Technology, Shenyang Sunshine Pharmaceutical Co., Ltd., and BIND Therapeutics, Inc.; and a strategic partnership with Asklepios BioPharmaceutical, Inc. for the development, manufacture, and commercialization of targeted therapeutics for adeno-associated virus gene therapies in the areas of high medical need. The company was founded in 2007 and is headquartered in Watertown, Massachusetts.Read More Beat the Market (BTM) Rank™ 3.4 Analyst's Opinion Consensus RatingSelecta Biosciences has received a consensus rating of Buy. The company's average rating score is 2.86, and is based on 6 buy ratings, 1 hold rating, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $8.17, Selecta Biosciences has a forecasted upside of 237.5% from its current price of $2.42.Amount of Analyst CoverageSelecta Biosciences has only been the subject of 2 research reports in the past 90 days. Previous Next 2.2 Community Rank Outperform VotesSelecta Biosciences has received 292 “outperform” votes. (Add your “outperform” vote.)Underperform VotesSelecta Biosciences has received 380 “underperform” votes. (Add your “underperform” vote.)Community SentimentSelecta Biosciences has received 56.55% “underperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Selecta Biosciences and other stocks. Vote “Outperform” if you believe SELB will outperform the S&P 500 over the long term. Vote “Underperform” if you believe SELB will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldSelecta Biosciences does not currently pay a dividend.Dividend GrowthSelecta Biosciences does not have a long track record of dividend growth. Previous Next 1.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Selecta Biosciences insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $8,040.00 in company stock.Percentage Held by InsidersOnly 19.00% of the stock of Selecta Biosciences is held by insiders.Percentage Held by Institutions57.20% of the stock of Selecta Biosciences is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Selecta Biosciences are expected to grow in the coming year, from ($0.55) to ($0.18) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Selecta Biosciences is -2.42, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Selecta Biosciences is -2.42, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioSelecta Biosciences has a P/B Ratio of 24.20. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next Analyst Opinion: 3.4Community Rank: 2.2Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.6 5 -4 -3 -2 -1 -Overall Beat the Market Rank™1.45 out of 5 stars Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:SELB Previous Symbol CUSIPN/A CIK1453687 Webselectabio.com Phone617-923-1400Debt Debt-to-Equity RatioN/A Current Ratio2.71 Quick Ratio2.71Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$6.68 million Price / Sales38.82 Cash FlowN/A Price / Cash FlowN/A Book Value$0.10 per share Price / Book24.20Profitability EPS (Most Recent Fiscal Year)($1.22) Net Income$-55,350,000.00 Net MarginsN/A Return on Equity-1,206.08% Return on Assets-83.19%Miscellaneous Employees39 Outstanding Shares107,143,000Market Cap$259.29 million Next Earnings Date11/13/2020 (Estimated) OptionableOptionable $2.42 +0.06 (+2.54 %) (As of 09/25/2020 12:00 AM ET) 30 days | 90 days | 365 days | Advanced Chart Receive SELB News and Ratings via Email Sign-up to receive the latest news and ratings for SELB and its competitors with MarketBeat's FREE daily newsletter. Selecta Biosciences (NASDAQ:SELB) Frequently Asked Questions How has Selecta Biosciences' stock been impacted by Coronavirus? Selecta Biosciences' stock was trading at $3.09 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, SELB stock has decreased by 21.7% and is now trading at $2.42. View which stocks have been most impacted by COVID-19. Do Wall Street analysts recommend investors buy shares of Selecta Biosciences? 7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Selecta Biosciences in the last year. There are currently 1 hold rating and 6 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Selecta Biosciences. When is Selecta Biosciences' next earnings date? Selecta Biosciences is scheduled to release its next quarterly earnings announcement on Friday, November 13th 2020. View our earnings forecast for Selecta Biosciences. How were Selecta Biosciences' earnings last quarter? Selecta Biosciences Inc (NASDAQ:SELB) announced its quarterly earnings results on Thursday, August, 6th. The company reported ($0.25) earnings per share for the quarter, missing the Zacks' consensus estimate of $0.32 by $0.57. View Selecta Biosciences' earnings history. What price target have analysts set for SELB? 7 brokerages have issued 1-year price objectives for Selecta Biosciences' stock. Their forecasts range from $4.00 to $13.00. On average, they expect Selecta Biosciences' stock price to reach $8.17 in the next year. This suggests a possible upside of 237.5% from the stock's current price. View analysts' price targets for Selecta Biosciences. Who are some of Selecta Biosciences' key competitors? Some companies that are related to Selecta Biosciences include Nabriva Therapeutics (NBRV), Athenex (ATNX), Rhythm Pharmaceuticals (RYTM), Phathom Pharmaceuticals (PHAT), Theravance Biopharma (TBPH), Nkarta (NKTX), Arcturus Therapeutics (ARCT), Zogenix (ZGNX), BioXcel Therapeutics (BTAI), Arvinas (ARVN), I-Mab (ARQT), Retrophin (RTRX), Constellation Pharmaceuticals (CNST), Gossamer Bio (GOSS) and Vectura Group (VEGPF). View all competitors. What other stocks do shareholders of Selecta Biosciences own? Based on aggregate information from My MarketBeat watchlists, some companies that other Selecta Biosciences investors own include Inovio Pharmaceuticals (INO), VBI Vaccines (VBIV), SCYNEXIS (SCYX), Sorrento Therapeutics (SRNE), Novavax (NVAX), Rigel Pharmaceuticals (RIGL), Dynavax Technologies (DVAX), Geron (GERN), Catalyst Pharmaceuticals (CPRX) and Viking Therapeutics (VKTX). Who are Selecta Biosciences' key executives? Selecta Biosciences' management team includes the following people: Dr. Carsten Brunn, CEO, Pres & Director (Age 49, Pay $942.52k)Ms. Elona Kogan J.D., Esq., Gen. Counsel & Corp. Sec. (Age 51, Pay $480.77k)Mr. Stephen Smolinski, Chief Commercial Officer (Age 55, Pay $549.39k)Dr. Ulrich H. von Andrian-Werburg M.D., Ph.D., Co-Founder and Co-Chair of the Scientific Advisory BoardMr. Bradford D. Dahms, CFO, Principal Financial Officer & Principal Accounting Officer (Age 32) When did Selecta Biosciences IPO? (SELB) raised $64 million in an IPO on Wednesday, June 22nd 2016. The company issued 4,300,000 shares at $14.00-$16.00 per share. UBS Investment Bank and Stifel served as the underwriters for the IPO and Canaccord Genuity and Needham & Company were co-managers. What is Selecta Biosciences' stock symbol? Selecta Biosciences trades on the NASDAQ under the ticker symbol "SELB." Who are Selecta Biosciences' major shareholders? Selecta Biosciences' stock is owned by a number of institutional and retail investors. Top institutional shareholders include BVF Inc. IL (7.74%), Mangrove Partners (6.11%), Artal Group S.A. (2.71%), Marshall Wace North America L.P. (2.66%), FMR LLC (2.35%) and FMR LLC (2.35%). Company insiders that own Selecta Biosciences stock include Amir Nashat, Carsten Brunn and Timothy C Barabe. View institutional ownership trends for Selecta Biosciences. Which major investors are selling Selecta Biosciences stock? SELB stock was sold by a variety of institutional investors in the last quarter, including Wasatch Advisors Inc., Artal Group S.A., Orbimed Advisors LLC, Bank of America Corp DE, and Goldman Sachs Group Inc.. View insider buying and selling activity for Selecta Biosciences. Which major investors are buying Selecta Biosciences stock? SELB stock was bought by a variety of institutional investors in the last quarter, including BVF Inc. IL, Marshall Wace North America L.P., FMR LLC, FMR LLC, Mangrove Partners, Driehaus Capital Management LLC, Nuveen Asset Management LLC, and Jacobs Levy Equity Management Inc.. Company insiders that have bought Selecta Biosciences stock in the last two years include Amir Nashat, and Timothy C Barabe. View insider buying and selling activity for Selecta Biosciences. How do I buy shares of Selecta Biosciences? Shares of SELB can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is Selecta Biosciences' stock price today? One share of SELB stock can currently be purchased for approximately $2.42. How big of a company is Selecta Biosciences? Selecta Biosciences has a market capitalization of $259.29 million and generates $6.68 million in revenue each year. The company earns $-55,350,000.00 in net income (profit) each year or ($1.22) on an earnings per share basis. Selecta Biosciences employs 39 workers across the globe. What is Selecta Biosciences' official website? The official website for Selecta Biosciences is selectabio.com. How can I contact Selecta Biosciences? Selecta Biosciences' mailing address is 65 Grove Street, Watertown MA, 02472. The company can be reached via phone at 617-923-1400 or via email at [email protected] This page was last updated on 9/26/2020 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here Questions? Get Started with MarketBeat — Read Your Daily NewsletterCheck Out My MarketBeatWatch Our Tutorial VideosAdd a Stock to Your WatchlistSet Up an Instant AlertView a Company's Profile PageView Our Financial CalendarsView Today's Analyst Ratings
